Continuum Advisory, LLC Neurocrine Biosciences Inc Transaction History
Continuum Advisory, LLC
- $773 Million
- Q2 2025
A detailed history of Continuum Advisory, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Continuum Advisory, LLC holds 36,587 shares of NBIX stock, worth $5.1 Million. This represents 0.6% of its overall portfolio holdings.
Number of Shares
36,587
Previous 27
135407.41%
Holding current value
$5.1 Million
Previous $2,000
229800.0%
% of portfolio
0.6%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
101MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.98 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.37 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$776 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$623 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$430 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...